Trial · NCT01883440
Glucose Oxidase as Treatment Against Common Cold
NCT01883440, Phase 2, Completed, Krister Tano; results first posted 2016-01-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glucose Oxidase as Treatment Against Common Cold. Trials, record NCT01883440. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01883440
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glucose Oxidase as Treatment Against Common Cold
- NCT number
- NCT01883440
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 90 participants, actual
- Lead sponsor
- Krister Tano
- Conditions
- Common Cold
- Interventions
- Glucose oxidase + glucose, Saline+glucose
- First posted
- 2013-06-21
- Last updated
- 2016-01-27
- Results first posted
- 2016-01-27
- Limitations and caveats
Viral samplings were made in order to exclude persons with no viral infection and persons with influenza. Most common Colds are due to Rhinoviruses, Parainfluenza and Coronaviruses. These persons were included in the Groups with significant findings.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sum of All Symptoms in Viruspositive Persons | One week | Symptoms of a common cold, recorded in a home protocol, "Wisconsin Upper Respiratory Symptom Score 21 (WURSS21)" daily for 7 days was used as the evaluation method of the treatment. WURSS-21 is a validated protocol for assessing symptoms of a common cold. We used this protocol at start, before the persons in the study started their treatment and thereafter every day for the next 7 days. WURSS 21 consists of 21 questions (last question is not valid) regarding different symptoms as: running nose, sore throat, cough, blocked nose, etc. Every such question is graded from 0-7, 0 is defined as no such symptom and the number 7 means the worst possible symptom. The outcome measure is predominantly calculated as "the sum of all symptoms" in the WURSS-21 protocol, which means that the value from each of the 20 questions (min=0, max=140) is summarized every day for each of the participants, which gives a mean value for both groups every day. |
| Primary | Sum of All Symptoms of All Persons That Fullfilled the Study | 7 days | Symptoms of a common cold, recorded in a home protocol, "Wisconsin Upper Respiratory Symptom Score 21 (WURSS21)" daily for 7 days was used as the evaluation method of the treatment. WURSS-21 is a validated protocol for assessing symptoms of a common cold. We used this protocol at start, before the persons in the study started their treatment and thereafter every day for the next 7 days. WURSS 21 consists of 21 questions (last question is not valid) regarding different symptoms as: running nose, sore throat, cough, blocked nose, etc. Every such question is graded from 0-7, 0 is defined as no such symptom and the number 7 means the worst possible symptom. The outcome measure is predominantly calculated as "the sum of all symptoms" in the WURSS-21 protocol, which means that the value from each of the 20 questions (min=0, max=140) is summarized every day for each of the participants, which gives a mean value for both groups every day. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Sum of All Symptoms in Viruspositive Persons | One week | The persons analyzed were those that had a positive viral sampling with Parainfluenza, Corona or Rhinoviruses, that is: the viruses that most often causes common cold and also would be accessible for treatment with a nasal spray. | units on a scale | MEAN |
| PRIMARY | Sum of All Symptoms of All Persons That Fullfilled the Study | 7 days | All of the persons that fullfilled the study | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Sum of All Symptoms in Viruspositive Persons | Saline+Glucose | Start value | 52 | Full Range 8 to 63 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Glucose Oxidase + Glucose | Start value | 52 | Full Range 18 to 92 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Saline+Glucose | Value day 1 | 54 | Full Range 8 to 84 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Glucose Oxidase + Glucose | Value day 1 | 56 | Full Range 14 to 81 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Saline+Glucose | Value day 2 | 58 | Full Range 13 to 95 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Glucose Oxidase + Glucose | Value day 2 | 53 | Full Range 8 to 108 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Saline+Glucose | Value day 3 | 52.5 | Full Range 7 to 80 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Glucose Oxidase + Glucose | Value day 3 | 38 | Full Range 2 to 106 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Saline+Glucose | Value day 4 | 48 | Full Range 2 to 83 | units on a scale |
| Sum of All Symptoms in Viruspositive Persons | Glucose Oxidase + Glucose | Value day 4 | 31 | Full Range 0 to 87 | units on a scale |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Saline+Glucose | 45 | |
| Overall Study | STARTED | Glucose Oxidase + Glucose | 45 | |
| Overall Study | COMPLETED | Saline+Glucose | 42 | |
| Overall Study | COMPLETED | Glucose Oxidase + Glucose | 45 | |
| Overall Study | NOT COMPLETED | Saline+Glucose | 3 | |
| Overall Study | NOT COMPLETED | Glucose Oxidase + Glucose | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Saline+Glucose | ||
| Total, all-cause mortality | Glucose Oxidase + Glucose | ||
| Total, other adverse events | Saline+Glucose | 0 | 45 |
| Total, other adverse events | Glucose Oxidase + Glucose | 0 | 45 |
| Total, serious adverse events | Saline+Glucose | 0 | 45 |
| Total, serious adverse events | Glucose Oxidase + Glucose | 0 | 45 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Saline+Glucose vs Glucose Oxidase + Glucose: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01883440
GET https://conductscience.org/api/trials/v1/NCT01883440/results?page=2